A comparative analysis of serum phosphorus levels and mineral metabolic markers in non-dialysis and dialysis chronic kidney disease patient: a cross-sectional study

Sanjeet Kumar Pandit; Aditya Vohra; Ashim Kumar Mahali; Karthikeyan Pandiyambakkam Rajendran

doi:10.18203/2394-6040.ijcmph20233838

Authors

Sanjeet Kumar Pandit Department of Nephrology, KB Clinics, Siliguri, West Bengal, India
Aditya Vohra Department of Nephrology, Neotia Multispeciality Hospital, Siliguri, West Bengal, India
Ashim Kumar Mahali Department of Nephrology, Kalinga Institute of Medical Sciences, KIIT University (Deemed), Bhubaneswar, Odisha, India
Karthikeyan Pandiyambakkam Rajendran Independent Researcher, Chennai, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20233838

Keywords:

Chronic kidney disease, Dialysis, Phosphorus, Serum, GFR, Calcium

Abstract

Background: Chronic kidney disease is a major public health problem worldwide. As kidney function declines, it leads to several metabolic abnormalities including dysregulation of mineral metabolism. It is also reported that hyperphosphatemia in patients with advanced kidney disease is associated with an increased risk of mortality and cardiovascular events, and is higher in dialysis-dependent chronic kidney disease (CKD) patients compared to non-dialysis CKD. However, data in the Indian context is limited. Objectives were to evaluate and compare serum phosphorus levels and associated factors in non-dialysis and dialysis CKD patients. Also, the impact of dietary phosphate restriction and the use of phosphate binders on serum phosphorus is analysed.

Methods: A cross-sectional study was conducted at a tertiary care hospital in Kolkata, India, with 100 CKD patients: 50 non-dialysis CKD patients and 50 dialysis-dependent CKD patients. Relevant demographic, clinical and laboratory parameters including serum phosphorus, calcium, parathyroid hormone (PTH), alkaline phosphatase, albumin and estimated glomerular filtration rate (eGFR) were collected. Data was analyzed using appropriate statistical tests.

Results: Mean serum phosphorus was significantly higher in the dialysis CKD group (6.12±0.34 mg/dl) compared to the non-dialysis CKD group (4.56±0.80 mg/dl). Serum calcium and PTH were also higher while eGFR and albumin were lower in the dialysis CKD group. Serum phosphorus levels increased with advancing CKD stages in the non-dialysis group. Phosphate binder helped phosphorus control in dialysis CKD patients.

Conclusions: Our study is in confluence with other reports and dietary phosphate restriction and the use of phosphate binders help optimize phosphorus levels in CKD patients.

Metrics

Metrics Loading ...

References

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-130.

Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie E, Chertow G. Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis. J Am Soc Nephrol JASN. 2004;15:2208-18.

Kovesdy CP, Kopple JD, Kalantar-Zadeh K. Management of protein-energy wasting in non-dialysis-dependent chronic kidney disease: reconciling low protein intake with nutritional therapy. Am J Clin Nutr. 2013;97(6):1163-77.

Rajkondawar AV, Yele A. Clinico-biochemical profile of chronic kidney disease patients in elderly age group in a tertiary care centre. Int J Res Med Sci. 2019;7(11):4227-31.

Profile of incident chronic kidney disease related-mineral b: Indian Journal of Nephrology. Available at: https://journals.lww.com/ijon/Fulltext/2014/24020 /Profile_of_incident_chronic_kidney_disease.6.aspx. Accessed on 18 November, 2023.

Ma D, Yan H, Yang X, Yu Z, Ni Z, Fang W. Abdominal aortic calcification score as a predictor of clinical outcome in peritoneal dialysis patients: a prospective cohort study. BMC Nephrol. 2020;21(1):151.

Jorge BCA, Kevin JM. The challenge of controlling phosphorus in chronic kidney disease. Nephrol Dial Transplant. 2016;31(4):541-7.

Fellype CB, Daniela VB, Ziad AM, Tilman BD. Strategies for Phosphate Control in Patients With CKD. Kidney Int Rep. 2019;4(8):1043-56.

Toussaint ND, Holt SG. Is serum phosphate a useful target in patients with chronic kidney disease and what is the role for dietary phosphate restriction? Nephrol Carlton Vic. 2017;22(2):36-41.

Bhandari SK, Liu ILA, Kujubu DA, Huynh T, Behayaa H, Kovesdy CP et al. Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes. Am J Nephrol. 2017;45(5):431-41.

Chan S, Au K, Francis RS, Mudge DW, Johnson DW, Pillans PI. Phosphate binders in patients with chronic kidney disease. Aust Prescr. 2017;40(1):10-4.

Suki WN, Moore LW. Phosphorus Regulation in Chronic Kidney Disease. Methodist DeBakey Cardiovasc J. 2016;12(4):6-9.

Sherman RA, Ravella S, Kapoian T. A dearth of data: the problem of phosphorus in prescription medications. Kidney Int. 2015;87(6):1097-9.

Kim GH, Choi BS, Cha DR, Chee DH, Hwang E, Kim HW et al. Serum calcium and phosphorus levels in patients undergoing maintenance hemodialysis: A multicentre study in Korea. Kidney Res Clin Pract. 2014;33(1):52-7.

Elmukhtar H, Mohsen E, Fahmi K, Abdel-Naser YE. Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management. Cureus. 2021;13(7):e16388.

Jahan I, Ahmed S, Islam MR, Hai ANMA, Islam MF, Bhuiyan MA et al. Association of ORAI1 Genetic Polymorphism with Serum Calcium and Phosphorus Levels in Non-dialysis Chronic Kidney Disease Patients: A Case-control Study. Cureus. 2019 Apr 29;11(4):e4564.

Jiameng L, Liya W, Mei H, Yuqin X, Ruoxi L, Yupei L et al. The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease. Nutrit Diabetes. Nutr Diabetes. 2019;9(1):14.

Masyeni S, Wardani NS, Budiyasa DGA, Sadguna DM. Serum Phosphate Level among Chronic Kidney Disease Patients on Chronic Dialysis. Biomed Pharmacol J. 2020;13(1):207-11.

Bellasi A, Mandreoli M, Baldrati L, Corradini M, Di Nicolò P, Malmusi G et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol CJASN. 2011;6(4):883-91.

Valson AT, Sundaram M, David VG, Deborah MN, Varughese S, Basu G, et al. Profile of incident chronic kidney disease related-mineral bone disorders in chronic kidney disease Stage 4 and 5: A hospital based cross-sectional survey. Indian J Nephrol. 2014;24(2):97.

Nafar M, Sabaghian T, Khoshdel A, Alipour B, Samavat S. Serum Calcium and Phosphorus Levels in Hemodialysis Patients: A Large Population-Based Multicenter Study. Iran Red Crescent Med J. 2019.

Tonelli M. Serum phosphorus in people with chronic kidney disease: you are what you eat. Kidney Int. 2013;84(5):871-3.

Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74(2):148-57.

Martins CTB, Biavo BMM, Uezima CBB, Santos JAPD, Barros CM de, Ribeiro Júnior E et al. EPIC Trial: education programme impact on serum phosphorous control in CKD 5D patients on hemodialysis. J Bras Nefrol. 2017;39(4):398-405.

Fernández-Martín JL, Martínez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2015;30(9):1542-51.

Amin N, Mahmood RT, Asad M, Noorulamin M. Evaluating Urea and Creatinine Levels in Chronic Renal Failure Pre and Post Dialysis: A Prospective Study. 2014;2:2330-4596.

Stel VS, Dekker FW, Ansell D, Augustijn H, Casino FG, Collart F et al. Residual renal function at the start of dialysis and clinical outcomes. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2009;24(10):3175-82.

O’Hare AM, Wong SP, Yu MK, Wynar B, Perkins M, Liu CF et al. Trends in the Timing and Clinical Context of Maintenance Dialysis Initiation. J Am Soc Nephrol JASN. 2015;26(8):1975-81.

Singleton JR, Smith AG, Russell J, Feldman EL. Polyneuropathy with Impaired Glucose Tolerance: Implications for Diagnosis and Therapy. Curr Treat Options Neurol. 2005;7(1):33-42.